428 POSTER A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors
Y. Onozawa, N. Boku, A. Fukutomi, A. Ohtsu, T. Doi, T. Yoshino, W. Koizumi, S. Tanabe, T. SasakiVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72362-0
File:
PDF, 104 KB
english, 2008